Changing the way type 2 diabetes is managed

Abstract

A number of well organised randomised control trials have demonstrated benefits of sodium-glucose cotransporter 2 Inhibitors and glucagon-like peptide 1 receptor agonists in reducing major adverse cardiac events. Secondary endpoints for SGLT-2is have also shown improvement in outcomes for those with heart failure with reduced ejection fraction and chronic kidney disease with albuminuria. These therapeutic advantages enable risk stratification and for treatment to be individualised depending on patient baseline characteristics. This article discusses the place of different therapeutic agents in the treatment of type 2 diabetes and describes why we should adopt a holistic approach in managing the cardio-renal risk associated with type 2 diabetes in light of the current best practice evidence.